Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of LBL-007 combined with tislelizumab in malignant tumors
CTR20222059Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alcestobart in Non-hematologic malignancy, sponsored by Leads Biolabs. Started Sep 2022; status: completed.
02
Drugs
alcestobart
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20222059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222059.